Fig. 1: CONSORT flow diagram of patient disposition in the ENDURE trial. | Leukemia

Fig. 1: CONSORT flow diagram of patient disposition in the ENDURE trial.

From: Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX)

Fig. 1

Of 223 patients screened, 9 (4.0%) did not meet the eligibility criteria. A total of 214 patients (96%) were randomized to either ropeginterferon alfa-2b (AOP2014; n = 101) or surveillance (n = 113). After randomization, 11 patients (4.9%) were excluded from the analysis. The final analysis population comprised 95 patients in the ropeg-IFN arm and 108 patients in the surveillance arm. COVID coronavirus disease, MMR major molecular remission, PegIFN pegylated interferon.

Back to article page